Polynovo Limited: Receives AU$10 million Increase in BARDA Funding

PolyNovo Limited (ASX: PNV) has secured an additional AU$10 million in funding from BARDA, boosting the total commitment to AU$25 million for its NovoSorb® BTM Pivotal Trial program. The objective of this funding is to analyze the performance of NovoSorb® BTM in addressing full-thickness burns. Successful trial completion may pave the way for FDA approval and the use of NovoSorb® BTM in disaster management.

While NovoSorb BTM is already approved in select markets and holds the CE Mark for various medical procedures, this continued funding underscores BARDA's confidence in PolyNovo's groundbreaking medical solutions. Since its initiation in 2015, the BARDA contract has made significant progress, with participation from multiple U.S. and Canadian sites and plans to include additional sites in India. This financial support highlights the importance of PolyNovo's work in advancing treatments for severe burns.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com